ATTR Salesforce

















































$1000/month car allowance. No EV requirements. Territory Representatives $185k base $45k target bonus. Stock options. Indications Poly Neuropathy and Cardiomyopathy for wild type and familial all at launch.
 




















Problem is BridgeBio can't compete with Pfizer's Vyndamax and Acoramidis dosing schedule will make it an unlikely treatment for first line. Plus pfizer can launch AG and bridgebio have nothing else going on in their pipeline either.
 




$1000/month car allowance. No EV requirements. Territory Representatives $185k base $45k target bonus. Stock options. Indications Poly Neuropathy and Cardiomyopathy for wild type and familial all at launch.

the PN phase three trial was abandoned and I've seen no evidence of any secondary endpoints in their CM data. If they get PN it would be pulling a rabbit out of a hat. The CM composite endpoints are a gimmick. They had better price it cheap!